---
author: mike
pubDatetime: 2024-04-28 19:03:01.633361
modDatetime: 2024-04-28 19:03:01.633361
title: Q124 ABBV earnings
slug: q124-abbv-earnings
featured: false
ogImage: /assets/images/250_250.png
tags:
- transcripts
- earnings
- biotech
description: Earnings summary for Q124 AbbVie
---
### Earnings Results
- **First Quarter Revenue**: $12.3 billion, approximately $400 million ahead of expectations.
- **Adjusted Earnings Per Share**: $2.31, which is $0.11 above the guidance midpoint.
- **Immunology Revenue**: Total revenues of approximately $5.4 billion, exceeding expectations.
  - **SKYRIZI Global Sales**: $2 billion, reflecting operational growth of 48%.
  - **RINVOQ Global Sales**: Approximately $1.1 billion, reflecting operational growth of 61.9%.
- **HUMIRA Global Sales**: Approximately $2.3 billion, down 35.2% on an operational basis due to biosimilar competition in the U.S.
- **Oncology Total Revenues**: More than $1.5 billion, exceeding expectations.
- **Neuroscience Total Revenues**: Nearly $2 billion, up 16% on an operational basis.
- **Global Aesthetics Sales**: Over $1.2 billion, with a modest decline on an operational basis.

### Future Guidance
- **Adjusted Earnings Per Share Guidance for Full Year**: Raised by $0.16, now expecting between $11.13 and $11.33.
- **Long-term Outlook**: High single-digit revenue CAGR (Compound Annual Growth Rate) anticipated through the end of the decade.
- **SKYRIZI**: Expected to add more than $1 billion of incremental sales growth this year.
- **RINVOQ**: Projected strong performance across all approved indications.

### Trends, Market Conditions, Sentiment
- **SKYRIZI**: Demonstrating exceptional momentum across all approved indications, achieving in-play share leadership in nearly 30 key countries.
- **RINVOQ**: Significant prescription growth across four approved indications, capturing high-teens in-play patient share in ulcerative colitis and Crohn's disease.
- **Biosimilar Competition**: HUMIRA's U.S. market erosion slightly better than expected, primarily driven by price.
- **Oncology**: Solid performance despite competitive pressures, with new approvals adding to long-term growth.
- **Neuroscience**: Continued double-digit growth driven by key assets like Vraylar, Ubrelvy, and Qulipta.
- **Global Aesthetics Market**: Showing signs of recovery, especially in facial injectables in the U.S. Economic headwinds in China impacted growth, with expectations of recovery in the second half of the year.
- **Investments in R&D**: AbbVie highlighted substantial increases in R&D investments for the future, emphasizing the importance of innovation to sustain long-term growth.
- **Business Development**: Strategic acquisitions and collaborations aimed at strengthening the portfolio, particularly in oncology and immunology, suggesting a proactive approach to addressing future challenges and capitalizing on growth opportunities.

### Notable Quotes
- Rick Gonzalez on CEO Transition: "Our business is performing very well and is in a strong position for the long term."
- Rob Michael on AbbVieâ€™s Performance: "We're off to an excellent start to the year with strong top and bottom line results."
- Jeff Stewart on Immunology Performance: "SKYRIZI and RINVOQ growth above 50% in their fifth full year on the market...demonstrates the strength of our diversified portfolio."
- Carrie Strom on Aesthetics Trends: "The underlying trends across our aesthetics portfolio align well with our previous expectations..."
- Roopal Thakkar on R&D Advances: "We continue to make very good progress with our inflammatory bowel disease programs..."